Nov 15, 2022 / 09:10PM GMT
Dae Gon Ha - Stifel Financial Corp. - Analyst
All right. Good afternoon, everyone. Thanks for joining this next session. My name is Dae Gon Ha, one of the biotech analysts here at Stifel. With me for the next half hour-ish, we have Homology Medicines. And with me on stage, we've got the President and CEO, Albert Seymour. So Albert, thanks very much for joining us. This is my first time seeing you after you became the CEO. So thanks for that.
Questions and Answers:
Dae Gon Ha - Stifel Financial Corp. - AnalystMaybe if we can just start off with a brief overview of Homology, programs that you've got going in the catalysts for the next 6 to 12 months-ish.
Albert Seymour - Homology Medicines, Inc. - President & CEO
Yes, happy to dig on. So within the catalysts and within the company right now, we're continuing to progress. We have two programs that we're really excited about that are in Phase 1 right now. Ones are the first in-vivo gene editing program for PKU, HMI-103; again in Phase 1. In parallel with that,
Trustpilot
